RxDoctor Payments Data

Melissa French, APRN

Psychiatric/Mental Health · Manchester, NHNPI 1306184957

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 40.9% of the total.

$2,159in general payments, 2019–2025

Across 135 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$883
  • Lundbeck LLC$463
  • Axsome Therapeutics, Inc.$238
  • Sunovion Pharmaceuticals Inc.$236
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$107
  • Alkermes, Inc.$96
  • plus $137 from 4 others

What the payments were for

  • Food & beverage$2,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 85th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$16,396
Medicare patients
35
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$87,937
RexultiBrexpiprazole36$58,067
VraylarCariprazine Hcl21$38,521
LatudaLurasidone Hcl26$35,585
Divalproex Sodium ErDivalproex Sodium22$3,002
Divalproex Sodium58$3,000
Oxcarbazepine36$2,864
Olanzapine57$1,907
Prazosin Hcl45$1,877
Aripiprazole30$1,872
Bupropion XlBupropion Hcl45$1,227
Quetiapine Fumarate ErQuetiapine Fumarate31$1,155
Clozapine36$1,061
Haloperidol22$1,018
Quetiapine Fumarate39$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$883$38,52121 claims
Sunovion Pharmaceuticals Inc.Latuda$236$35,58526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →